David Wojciechowski, DO
Nephrology · Dallas, TXNPI 1013976844
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Veloxis Pharmaceuticals, Inc. at 32.0% of the total. 2025 is the largest year on record at $11,415, 4.5 times the $2,529 reported in 2019. Among nephrology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $554.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veloxis Pharmaceuticals, Inc.$9K
- E.r. Squibb & Sons, L.L.C.$6K
- Pierre Fabre Pharmaceuticals, Inc.$5K
- Apellis Pharmaceuticals, Inc.$3K
- CSL Behring$3K
- Mallinckrodt Enterprises LLC$2K
- plus $547 from 5 others
Across 131 payments — averaging $11,813 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Transmedics, Inc.$458K
- Amgen$326K
- Novartis$222K
- CSL Behring$208K
- Nobelpharma America, LLC$120K
- Astellas Pharma Global Development$95K
- plus $118K from 3 others
What the payments were for
- Consulting fees$16,21358%
- Speaking & faculty fees$3,75014%
- Travel & lodging$3,79614%
- Food & beverage$2,2238%
- Education$1,7636%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veloxis Pharmaceuticals, Inc. | 10 | $8,890 |
| E.r. Squibb & Sons, L.L.C. | 10 | $5,690 |
| Pierre Fabre Pharmaceuticals, Inc. | 7 | $4,695 |
| Apellis Pharmaceuticals, Inc. | 1 | $3,147 |
| CSL Behring | 12 | $2,610 |
| Mallinckrodt Enterprises LLC | 3 | $2,166 |
| Biogen | 3 | $330 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Kamada Ltd. | 1 | $57 |
| Amgen | 1 | $35 |
| AstraZeneca | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Envarsus$8,955
- ACTHAR$2,140
- NULOJIX$1,999
- THYMOGLOBULIN$100
How this compares
$27,745 in reported general payments places this provider in the 90th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 13 | $8,640 |
| Valganciclovir Hcl | 16 | $4,255 |
| Nifedipine ErNifedipine | 24 | $677 |
| Pantoprazole Sodium | 31 | $407 |
| Carvedilol | 42 | $285 |
| Atorvastatin Calcium | 39 | $264 |
| Prednisone | 48 | $248 |
| Tamsulosin Hcl | 30 | $211 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $186 |
| Amlodipine Besylate | 46 | $112 |
| Losartan Potassium | 14 | $91 |
| Furosemide | 25 | $79 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Dallas
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Irfan AghaDallas$415K
- Russell SilversteinDallas$204K
- Sumit KumarDallas$166K
- Christopher HebertDallas$102K
- Robert TotoDallas$87K
- Michael WiederkehrDallas$82K
- Samir ParikhDallas$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.